SCHEMBL19124

SCHEMBL19124

[c]1cccc2cnoc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130886 0.65
SCHEMBL17941619 0.65
SCHEMBL23473 0.64
SCHEMBL450905 0.62
Benzo[D]Isoxazole SCHEMBL1355530 0.62
Benzo[D]Isoxazole SCHEMBL8438 0.62
SCHEMBL60224 0.61 CYP2A6 (0.38)
SCHEMBL286537 0.61
SCHEMBL1487929 0.61
SCHEMBL129743 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3210 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 EP claimed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 US claimed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 EP claimed
US-20200031799-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 US claimed
US-20200031800-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 US claimed
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-08-29 US claimed
US-20190263818-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-08-29 US claimed
US-10308637-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-06-04 US claimed
EP-3481391-A1 THERAPEUTIC INHIBITORY COMPOUNDS Lifesci Pharmaceuticals, Inc. (BB) 2019-05-15 EP claimed
US-20190002437-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-01-03 US claimed
EP-1147114-B1 NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY ASTRAZENECA AB (SE) 2003-05-21 EP claimed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP claimed
WO-2002076976-A2 RHO-KINASE INHIBITORS BAYER CORPORATION (US) 2002-10-03 WO claimed
EP-1147114-A1 NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY AstraZeneca AB (SE) 2001-10-24 EP claimed
WO-2001068605-A1 POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-09-20 WO claimed
WO-2000042044-A1 NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY ASTRAZENECA AB (SE) 2000-07-20 WO claimed
WO-1999045013-A1 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES NOVO NORDISK A/S (DK) 1999-09-10 WO claimed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US claimed
EP-0822187-A1 PYRAZOLE DERIVATIVES AND HERBICIDES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1998-02-04 EP claimed
US-5401738-A Angiotensin antagonist, hypotensive, aldosteronism, cardiac insufficiency MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) 1995-03-28 US claimed